Travel Medicine and Infectious Disease
Published by Elsevier
ISSN : 1477-8939 eISSN : 1873-0442
Abbreviation : Travel Med. Infect. Dis.
Aims & Scope
Travel Medicine and Infectious Disease publishes original papers, reviews and consensus papers that have a primary theme of infectious disease in the context of travel medicine.
Focus areas include: epidemiology and surveillance of travel-related illness, prevention and treatment of travel associated infections, malaria prevention and treatment, travellers' diarrhoea, infections associated with mass gatherings, migration-related infections, vaccines and vaccine-preventable disease, global policy/regulations for disease prevention and control, and practical clinical issues for travel and tropical medicine practitioners.
The journal also covers areas of controversy and debate in travel medicine particularly where this may inform guidelines and policy pertinent to travel medicine and the prevention of infectious disease.
Travel Medicine and Infectious Disease aims to publish cutting edge papers and offers a fast peer-review process with early online publication of accepted manuscripts.
View Aims & ScopeMetrics & Ranking
Impact Factor
| Year | Value |
|---|---|
| 2025 | 4.7 |
| 2024 | 6.30 |
SJR (SCImago Journal Rank)
| Year | Value |
|---|---|
| 2024 | 0.955 |
Quartile
| Year | Value |
|---|---|
| 2024 | Q1 |
h-index
| Year | Value |
|---|---|
| 2024 | 77 |
Journal Rank
| Year | Value |
|---|---|
| 2024 | 5225 |
Journal Citation Indicator
| Year | Value |
|---|---|
| 2024 | 1514 |
Impact Factor Trend
Abstracting & Indexing
Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.
Subjects & Keywords
Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.
Licensing & Copyright
This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.
Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.
Policy Links
This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.
- Aims scope
- Homepage
- Oa statement
- Author instructions
- License terms
- Review url
- Board url
- Copyright url
- Plagiarism url
- Preservation url
- Apc url
- License
Plagiarism Policy
This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.
For more details, please refer to our official: Plagiarism Policy.
APC Details
The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.
This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 3,220.00 USD. Learn more.
Explore journals without APCs for alternative publishing options.
Most Cited Articles
The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.
-
Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis
Citation: 1673
Authors: Alfonso J., Jaime A., EstefanÃa, Rhuvi, Yeimer, Juan Pablo, Lucia Elena, D. Katterine, Carlos, Andrés F., Alberto, Guillermo J., Eduardo, Jose A., Lysien I., Wilmer E., Graciela J., Ali A., Harapan, Kuldeep, Hiroshi, Hiromitsu, Tauseef, Ranjit
-
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Citation: 547
Authors: Philippe, Jean-Christophe, Philippe, Van Thuan, Line, Jacques, Morgane, Barbara, Camille, Sophie, Piseth, Marie, Carole, Julie, Vera Esteves, Hervé Tissot, Stéphane, Andreas, Matthieu, Philippe, Bernard, Véronique, Alexis, Jean-Claude, Michel, Pierre Edouard, Jean-Marc, Philippe, Didier
-
Efficacy of face mask in preventing respiratory virus transmission: A systematic review and meta-analysis
Citation: 364
Authors: Mingming, Liang, Ce, Qin, John Patrick, Kurt, Chenyu
-
COVID-19 in Latin America: The implications of the first confirmed case in Brazil
Citation: 352
Authors: Alfonso J., Viviana, Juan Pablo, Claudio A., Lysien I., Carlos, Jose A., Hernan D., Graciela Josefina, Eduardo, Alejandro, Sergio
-
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Citation: 333
Authors: Matthieu, Jean-Christophe, Philippe, Philippe, Pierre-Edouard, Sophie, Marie, Morgane, Vera, Barbara, Camille, Florian, Audrey, Yanis, Cyril, Nadim, Piseth, Christine, Catherine, Isabelle, Christelle, Carole, Hervé, Stéphane, Andreas, Alexis, Jean-Claude, Eric, Anthony, Florence, Jean-Marc, Yolande, Philippe, Michel, Bernard, Philippe, Didier
-
Meta-analysis of probiotics for the prevention of traveler's diarrhea
Citation: 299
Authors: Lynne V.
-
COVID-19 social distancing in the Kingdom of Saudi Arabia: Bold measures in the face of political, economic, social and religious challenges
Citation: 252
Authors: Saber, Anas
-
Remdesivir as a possible therapeutic option for the COVID-19
Citation: 228
Authors: Jaffar A., Ali H., Ziad A.
-
A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
Citation: 221
Authors: Donald C., Hai-Feng
-
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
Citation: 219
Authors: Yu-chen, Qi-xin, Shi-xue